FDA Bulk Compounding Substance Review: Task For Advisory Committee – Or Sisyphus?
This article was originally published in The Pink Sheet Daily
Executive Summary
Six nominees for the compounding bulk drug substances list will be discussed during the first Pharmacy Compounding Advisory Committee Meeting since its restart, but trade group proposed more than 1,500 for review.
You may also be interested in...
FDA’s Advisory Committee Schedule Hints At Re-formulated Compounding Panel
The agency has not set a meeting date for the Pharmacy Compounding Drugs Advisory Committee, defunct since 2002, in its tentative schedule, but has included 13 vacancies on the panel in its list of committees in need of new members.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.